Compounds > proxibarbal
Page last updated: 2024-12-05

proxibarbal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

proxibarbal: was heading 1976-94 (see under BARBITURATES 1976-90); use BARBITURATES to search IPRONAL 1976-94 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID17336
CHEMBL ID2105233
CHEBI ID134928
SCHEMBL ID715014
MeSH IDM0224594

Synonyms (72)

Synonym
proxibarbal, (-)-
unii-y54bsx54cs
y54bsx54cs ,
42013-22-9
barbituric acid, 5-(2-propenyl)-5-(2-hydroxypropyl)
centralgol (tn)
D07324
proxibarbal (inn)
2537-29-3
hh 184
ipronal
5-(2-hydroxypropyl)-5-(2-propenyl)-2,4,6(1h,3h,5h)-pyrimidinetrione
centralgyl
barbituric acid, 5-allyl-5-(2-hydroxypropyl)-, (+-)-
proxibarbal
axeen
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propenyl)-
l-5-allyl-5-(2-hydroxypropyl)barbituric acid
dl-5-allyl-5-(beta-hydroxypropyl)barbituric acid
l-5-allyl-5-(beta-hydroxypropyl)barbituric acid
dl-5-allyl-5-(2-hydroxypropyl)barbituric acid
barbituric acid, 5-allyl-5-(2-hydroxypropyl)-, (-)-
hydroxydial
5-allilo-5-(beta-hydroksypropylo)-barbiturowy [polish]
barbituric acid, 5-allyl-5-(2-hydroxypropyl)-
ipronal, (+-)-
proxibarbalum [inn-latin]
kwas 5-allilo-5-(beta-hydroksy-propylo)barbiturowy [polish]
brn 0219840
centralgol
5-allyl-5-(beta-hydroxypropyl)malonylurea
einecs 219-803-4
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propenyl)-, (+-)-
proxibarbital
proxibarbal [inn]
CHEBI:134928
5-(2-hydroxypropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione
f97oms297f ,
unii-f97oms297f
5-allilo-5-(beta-hydroksypropylo)-barbiturowy
kwas 5-allilo-5-(beta-hydroksy-propylo)barbiturowy
proxibarbalum
42013-34-3
hh-184
CHEMBL2105233
SCHEMBL715014
proxibarbal [mart.]
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propen-1-yl)-
(+/-)-ipronal
proxibarbal [who-dd]
proxibarbal [mi]
VNLMRPAWAMPLNZ-UHFFFAOYSA-N
J-803051
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propenyl)-, (+)-
HY-101635
CS-6617
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propenyl)- (9ci)
DB13253
5-allyl-5-(2-hydroxypropyl)-barbituric acid
Q906452
DTXSID20862980
d-5-allyl-5-(.beta.-hydroxypropyl)barbituric acid
proxibarbal, (+)-
RE966VDY2Y ,
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propen-1-yl)-, (-)-
l-5-allyl-5-(.beta.-hydroxypropyl)barbituric acid
42013-23-0
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propenyl)-, (-)-
2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-hydroxypropyl)-5-(2-propen-1-yl)-, (+)-
unii-re966vdy2y
d-5-allyl-5-(beta-hydroxypropyl)barbituric acid
AKOS040753638
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
barbituratesMembers of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (4)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.00 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
barbituric acid
barbituric acid: RN given refers to parent cpd; structure from Merck Index, 9th ed, #966. barbituric acid : A barbiturate, the structure of which is that of perhydropyrimidine substituted at C-2, -4 and -6 by oxo groups. Barbituric acid is the parent compound of barbiturate drugs, although it is not itself pharmacologically active.		1.9310barbituratesallergen;
xenobiotic
ConditionIndicatedRelationship StrengthStudiesTrials
Neuroses
[description not available]		01.9310
Neurotic Disorders
Disorders in which the symptoms are distressing to the individual and recognized by him or her as being unacceptable. Social relationships may be greatly affected but usually remain within acceptable limits. The disturbance is relatively enduring or recurrent without treatment.		01.9310
Cerebral Concussion
[description not available]		01.9310
Acute Brain Injuries
[description not available]		01.9310
Brain Concussion
A nonspecific term used to describe transient alterations or loss of consciousness following closed head injuries. The duration of UNCONSCIOUSNESS generally lasts a few seconds, but may persist for several hours. Concussions may be classified as mild, intermediate, and severe. Prolonged periods of unconsciousness (often defined as greater than 6 hours in duration) may be referred to as post-traumatic coma (COMA, POST-HEAD INJURY). (From Rowland, Merritt's Textbook of Neurology, 9th ed, p418)		01.9310
Brain Injuries
Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.		01.9310
Glaucoma
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)		02.3420
Chronic Primary Open Angle Glaucoma
[description not available]		01.9410
Glaucoma, Open-Angle
Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.		01.9410